Apollon Wealth Management LLC lessened its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 17.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 7,463 shares of the financial services provider’s stock after selling 1,539 shares during the quarter. Apollon Wealth Management LLC’s holdings in iShares Biotechnology ETF were worth $1,087,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Highline Wealth Partners LLC acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $30,000. Bbjs Financial Advisors LLC acquired a new stake in shares of iShares Biotechnology ETF during the 2nd quarter worth approximately $31,000. Ashton Thomas Securities LLC acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $36,000. Voisard Asset Management Group Inc. acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $59,000. Finally, Chris Bulman Inc acquired a new stake in shares of iShares Biotechnology ETF during the 2nd quarter worth approximately $64,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Down 2.6 %
Shares of IBB stock opened at $140.09 on Friday. iShares Biotechnology ETF has a 52 week low of $116.70 and a 52 week high of $150.57. The firm has a 50 day moving average of $144.68 and a 200-day moving average of $141.56.
iShares Biotechnology ETF Announces Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- EV Stocks and How to Profit from Them
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- 10 Best Airline Stocks to Buy
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- What Are the U.K. Market Holidays? How to Invest and Trade
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.